It may promote tumor angiogenesis via the KH-type splicing regulatory protein (KHSRP)/von Hippel-Lindau (VHL)/Hypoxia-inducible factor-1 α (HIF1α)/vascular endothelial growth factor A (VEGFA) pathway, implying a potential therapeutic target for EBV-associated gastric carcinoma (Du et al., 2022b). This evidence concerns the gene VEGFA and gastric carcinoma.